- T. Kumbhar
According to a new report published by Introspective Market Research, titled, “Oligonucleotide Synthesis Market by Product, Application, and End User,” The Global Oligonucleotide Synthesis Market Size Was Valued at USD 10.49 Billion in 2023 and is Projected to Reach USD 12.45 Billion by 2032, Growing at a CAGR of 16% from 2024 to 2032.The global Oligonucleotide Synthesis Market is witnessing rapid growth, driven by the increasing demand for custom DNA and RNA sequences used in research, diagnostics, and therapeutic development. Oligonucleotides, short sequences of nucleotides, are fundamental tools in genetic testing, gene synthesis, PCR, and molecular diagnostics, enabling advancements in genomics and biotechnology.
This market is expanding due to the rising prevalence of genetic disorders and cancer, which has heightened the need for targeted genetic research and personalized medicine. Furthermore, advancements in biotechnology and next-generation sequencing (NGS) have increased the precision, speed, and affordability of oligonucleotide synthesis, boosting adoption across pharmaceutical, academic, and biotechnology sectors.
The Oligonucleotide Synthesis Market is segmented into Product, Application, and End User.
By Product, the market is categorized into Synthesized Oligonucleotides, Reagents, Equipment, and Services.
By Application, it is divided into Research, Diagnostics, and Therapeutics.
By End User, it is segmented into Pharmaceutical & Biotechnology Companies, Academic Research Institutes, and Contract Research Organizations (CROs).
A major driver of the oligonucleotide synthesis market is the growing demand for gene-based therapies and personalized medicine. As the understanding of genetic mechanisms deepens, oligonucleotides are increasingly being used in therapeutic applications such as antisense oligonucleotides, RNA interference (RNAi), and CRISPR gene editing. The surge in R&D investments by biopharma companies and the growing number of FDA approvals for oligonucleotide-based drugs further accelerate market expansion.
The expansion of synthetic biology and the integration of automation and AI in oligonucleotide synthesis present significant growth opportunities. Automation enhances production accuracy, scalability, and cost efficiency, while AI aids in optimizing sequence design and reducing synthesis errors. This technological synergy is expected to create new avenues for precision medicine, vaccine development, and molecular diagnostics in emerging markets.
Oligonucleotide Synthesis Market, Segmentation
The Oligonucleotide Synthesis Market is segmented on the basis of Product, Application, and End User.
Product:
The Product segment is further classified into Synthesized Oligonucleotides, Reagents, Equipment, and Services. Among these, the Synthesized Oligonucleotides sub-segment accounted for the highest market share in 2023. This is attributed to the increasing demand for custom DNA and RNA sequences used in genetic research, diagnostics, and drug development. The growing prevalence of genetic diseases and the adoption of oligonucleotide-based therapeutics have further boosted the demand for this segment.
Application:
The Application segment is further classified into Research, Diagnostics, and Therapeutics. Among these, the Research sub-segment accounted for the highest market share in 2023. The rise in genomics and molecular biology research, combined with increasing academic funding and industry collaborations, has led to higher consumption of oligonucleotides in laboratories and R&D centers globally.
Some of The Leading/Active Market Players Are:
- Thermo Fisher Scientific Inc. (U.S.)
- Agilent Technologies Inc. (U.S.)
- Bio-Rad Laboratories Inc. (U.S.)
- Integrated DNA Technologies (IDT) (U.S.)
- LGC Biosearch Technologies (U.K.)
- Eurofins Genomics (Germany)
- Twist Bioscience Corporation (U.S.)
- Biomers.net GmbH (Germany)
- GeneDesign Inc. (Japan)
- Trilink Biotechnologies (U.S.)
- GenScript Biotech Corporation (China)
- Bioneer Corporation (South Korea)
- ATDBio Ltd. (U.K.)
- Sangon Biotech (China)
- Maravai LifeSciences (U.S.)
- and other active players.
Key Industry Developments
In May 2024, Thermo Fisher Scientific launched its new high-throughput oligonucleotide synthesis platform to accelerate the production of gene and RNA-based therapeutic materials.
This innovation enhances synthesis accuracy and scalability, enabling faster drug discovery and vaccine development processes.
In January 2024, Twist Bioscience announced the expansion of its synthetic biology facility to increase oligonucleotide production capacity.
This strategic move aims to meet the growing global demand for custom DNA synthesis for research, diagnostics, and industrial applications.
Key Findings of the Study
- Synthesized Oligonucleotides segment dominated the market in 2023.
- Research applications accounted for the largest market share.
- North America led the global market due to strong biotech infrastructure.
- Growth driven by rising demand for personalized medicine and gene-based therapies.
- Integration of AI and automation shaping future synthesis processes.